Determination of receptor occupancy in the presence of mass dose: [ 11 C]GSK189254 PET imaging of histamine H 3 receptor occupancy by PF-03654746 von Gallezot, Jean-Dominique, Planeta, Beata, Nabulsi, Nabeel, Palumbo, Donna, Li, Xiaoxi, Liu, Jing, Rowinski, Carolyn, Chidsey, Kristin, Labaree, David, Ropchan, Jim, Lin, Shu-Fei, Sawant-Basak, Aarti, McCarthy, Timothy J, Schmidt, Anne W, Huang, Yiyun, Carson, Richard E

Volltext

Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746 von Gallezot, Jean-Dominique, Planeta, Beata, Nabulsi, Nabeel, Palumbo, Donna, Li, Xiaoxi, Liu, Jing, Rowinski, Carolyn, Chidsey, Kristin, Labaree, David, Ropchan, Jim, Lin, Shu-Fei, Sawant-Basak, Aarti, McCarthy, Timothy J, Schmidt, Anne W, Huang, Yiyun, Carson, Richard E

Volltext

P2‐074: Modulation of soluble APPα in brain by PF‐04995274, a 5HT4 partial agonist, following single oral doses in healthy human volunteers: Study design and PK‐PD analysis von Duvvuri, Sridhar, Nicholas, Timothy, Leurent, Claire, Raunig, David, Plotka, Anna, Schwam, Elias, Grimwood, Sarah, Rowinski, Carolyn, Rapp, Tracey L.

Volltext

P2‐074: Modulation of soluble APPα in brain by PF‐04995274, a 5HT 4 partial agonist, following single oral doses in healthy human volunteers: Study design and PK‐PD analysis von Duvvuri, Sridhar, Nicholas, Timothy, Leurent, Claire, Raunig, David, Plotka, Anna, Schwam, Elias, Grimwood, Sarah, Rowinski, Carolyn, Rapp, Tracey L.

Volltext

P3‐361: A randomized, double‐blind, sponsor‐unblinded, placebo‐ and positive‐controlled study to evaluate the effects of single oral administrations of PF‐04995274 on scopolamine‐i... von Leurent, Claire, Duvvuri, Sridhar, Raunig, David, Antinew, Jeremias, Rowinski, Carolyn, Zumpano, Laura, Bergeron, Michelle, Kocinsky, Hetal, Sieklucki, Joy, Nicolas, Timothy, Rapp, Tracey L.

Volltext

Systems pharmacology modeling in 5HT4: Prediction and outcome of a clinical scopolamine impairment trial and further application to Alzheimer's disease pathology von Nicholas, Timothy, Duvvuri, Sridhar, Leurent, Claire, Raunig, David, Rapp, Tracey L, Iredale, Phillip, Rowinski, Carolyn, Carr, Robert, Roberts, Patrick, Spiros, Athan, Geerts, Hugo

Volltext

A randomized, double-blind, sponsor-unblinded, placebo- and positive-controlled study to evaluate the effects of single oral administrations of PF-04995274 on scopolamine-induced d... von Leurent, Claire, Duvvuri, Sridhar, Raunig, David, Antinew, Jeremias, Rowinski, Carolyn, Zumpano, Laura, Bergeron, Michelle, Kocinsky, Hetal, Sieklucki, Joy, Nicolas, Timothy, Rapp, Tracey L

Volltext

P2‐400: Systems pharmacology modeling in 5HT4: Prediction and outcome of a clinical scopolamine impairment trial and further application to Alzheimer's disease pathology von Nicholas, Timothy, Duvvuri, Sridhar, Leurent, Claire, Raunig, David, Rapp, Tracey L., Iredale, Phillip, Rowinski, Carolyn, Carr, Robert, Roberts, Patrick, Spiros, Athan, Geerts, Hugo

Volltext

Modulation of soluble APPα in brain by PF-04995274, a 5HT4 partial agonist, following single oral doses in healthy human volunteers: Study design and PK-PD analysis von Duvvuri, Sridhar, Nicholas, Timothy, Leurent, Claire, Raunig, David, Plotka, Anna, Schwam, Elias, Grimwood, Sarah, Rowinski, Carolyn, Rapp, Tracey L

Volltext

P4‐234: Pharmacokinetics, safety and tolerability of PF‐04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease von Nicholas, Timothy, Raunig, David, Duvvuri, Sridhar, Plotka, Anna, Schwam, Elias, Grimwood, Sarah, Park, Yo‐sub, Rowinski, Carolyn, Rapp, Tracey L, Bergeron, Michelle, Leurent, Claire

Volltext

Pharmacokinetics, safety and tolerability of PF-04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease von Nicholas, Timothy, Raunig, David, Duvvuri, Sridhar, Plotka, Anna, Schwam, Elias, Grimwood, Sarah, Park, Yo-sub, Rowinski, Carolyn, Rapp, Tracey L, Bergeron, Michelle, Leurent, Claire

Volltext

Translational receptor occupancy for the 5-HT4 partial agonist PF-04995274 in rats, non-human primates and healthy volunteers von Grimwood, Sarah, Drummond, Elena, Zasadny, Ken, Skaddan, Marc, Brodney, Michael, Coffman, Karen, Nicholas, Timothy, Duvvuri, Sridhar, Raunig, David, Leurent, Claire, Rowinski, Carolyn, Park, Yo-Sub, Ogden, Adam, Sawant, Aarti, Miller, Emily, Rapp, Tracey L, Wang, Yi, Planeta-Wilson, Beata, Ropchan, Jim, Carson, Richard, Morris, Evan, Ding, Yu-Shin, Katz, Elyse

Volltext

P3‐431: Translational receptor occupancy for the 5‐HT4 partial agonist PF‐04995274 in rats, non‐human primates and healthy volunteers von Grimwood, Sarah, Drummond, Elena, Zasadny, Ken, Skaddan, Marc, Brodney, Michael, Coffman, Karen, Nicholas, Timothy, Duvvuri, Sridhar, Raunig, David, Leurent, Claire, Rowinski, Carolyn, Park, Yo‐Sub, Ogden, Adam, Sawant, Aarti, Miller, Emily, Rapp, Tracey L, Wang, Yi, Planeta‐Wilson, Beata, Ropchan, Jim, Carson, Richard, Morris, Evan, Ding, Yu‐Shin, Katz, Elyse

Volltext

Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial von Nicholas, Timothy, Duvvuri, Sridhar, Leurent, Claire, Raunig, David, Rapp, Tracey, Iredale, Phil, Rowinski, Carolyn, Carr, Robert, Roberts, Patrick, Spiros, Athan, Geerts, Hugo

Volltext

Safety and tolerability of a new formulation (90 mg/kg/day divided every 12 h) of amoxicillin/clavulanate (Augmentin) in the empiric treatment of pediatric acute otitis media cause... von Bottenfield, G W, Burch, D J, Hedrick, J A, Schaten, R, Rowinski, C A, Davies, J T

Volltext